AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair ValueSimplywall·37 minutes agoAZN-6.88%AZN
An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'MarketWatch·3 hours agoBMY+0.24%AZN-6.88%
H&M, EY to Speak at Consumer Goods Event Foregrounding Solutions To Drive ImpactMorningStar·4 hours agoHSBC+1.35%HSBH+1.59%
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.6% - Here's WhyMarket Beat·5 hours agoAAPG-3.56%HSBC+1.35%
AstraZeneca’s US tilt could be the death knell for London’s stock marketThe telegraph·6 hours agoAZN-6.88%AZN
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focusbenzinga_article·6 hours agoBMY+0.24%AZN-6.88%
Yen Intervention And Falling Oil Help Stocks, But Selling In Korea Throws A Monkey Wrenchbenzinga_article·7 hours agoBMY+0.24%MU+0.79%
Investors Buy Large Volume of Call Options on Astrazeneca (NYSE:AZN)Market Beat·8 hours agoAZN-6.88%BMY+0.24%
HSBC buys 2,237 Exail shares at EUR 124.63 during takeover offer filingsPUBT·8 hours agoHSBC+1.35%HSBH+1.59%
AstraZeneca PLC Stock (AZN) Moved Down by 8.54% on Aug 3: Key Drivers UnveiledTradingKey·8 hours agoAZN-6.88%AZN
AstraZeneca shares slump after $400bn BMS merger rumoursPharmaceutical Technology·9 hours agoAZN-6.88%AZN
AstraZeneca admits 8,855 new ordinary shares to London Stock Exchange main marketPUBT·9 hours agoAZN-6.88%AZN
Bristol Myers Squibb (NYSE:BMY) Sets New 12-Month High After Analyst UpgradeMarket Beat·10 hours agoBMY+0.24%AZN-6.88%
AIM ImmunoTech completes last dosing in Phase 2 DURIPANC trial of Ampligen plus AstraZeneca Imfinzi in metastatic pancreatic cancerPUBT·11 hours agoAIM+4.10%AZN-6.88%
